Susquehanna International Group
ESPR

Susquehanna International Group’s Esperion Therapeutics ESPR Stock Holding History

Susquehanna International Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.47M Sell
536,100
-4,700
-0.9% -$14.9K ﹤0.01% 6940
2025
Q4 		$2M Buy
540,800
+284,600
+111% +$920K ﹤0.01% 5663
2025
Q3 		$679K Buy
256,200
+212,300
+484% +$411K ﹤0.01% 8277
2025
Q2 		$43K Sell
43,900
-1,400
-3% -$1.4K ﹤0.01% 12150
2025
Q1 		$65.2K Sell
45,300
-179,200
-80% -$330K ﹤0.01% 11770
2024
Q4 		$494K Sell
224,500
-7,500
-3% -$17.5K ﹤0.01% 8697
2024
Q3 		$383K Sell
232,000
-702,800
-75% -$1.42M ﹤0.01% 9088
2024
Q2 		$2.08M Buy
934,800
+331,100
+55% +$779K ﹤0.01% 5034
2024
Q1 		$1.62M Buy
603,700
+490,600
+434% +$1.19M ﹤0.01% 5820
2023
Q4 		$338K Sell
113,100
-212,800
-65% -$276K ﹤0.01% 9574
2023
Q3 		$319K Sell
325,900
-5,400
-2% -$7.81K ﹤0.01% 9214
2023
Q2 		$461K Sell
331,300
-9,600
-3% -$13.4K ﹤0.01% 8518
2023
Q1 		$542K Sell
340,900
-249,300
-42% -$1.29M ﹤0.01% 8391
2022
Q4 		$3.68M Buy
590,200
+152,500
+35% +$1.09M ﹤0.01% 3703
2022
Q3 		$2.93M Sell
437,700
-71,900
-14% -$494K ﹤0.01% 4148
2022
Q2 		$3.24M Buy
509,600
+290,100
+132% +$1.64M ﹤0.01% 3923
2022
Q1 		$1.02M Buy
219,500
+53,000
+32% +$227K ﹤0.01% 7066
2021
Q4 		$833K Sell
166,500
-164,300
-50% -$1.32M ﹤0.01% 7783
2021
Q3 		$3.99M Buy
330,800
+210,100
+174% +$3.06M ﹤0.01% 4370
2021
Q2 		$2.55M Buy
120,700
+71,600
+146% +$1.72M ﹤0.01% 5374
2021
Q1 		$1.38M Sell
49,100
-37,300
-43% -$1.1M ﹤0.01% 6885
2020
Q4 		$2.25M Sell
86,400
-144,600
-63% -$4.33M ﹤0.01% 4848
2020
Q3 		$8.59M Buy
231,000
+142,100
+160% +$5.63M ﹤0.01% 2358
2020
Q2 		$4.56M Buy
88,900
+52,200
+142% +$2.18M ﹤0.01% 3130
2020
Q1 		$1.16M Sell
36,700
-98,500
-73% -$5.2M ﹤0.01% 5068
2019
Q4 		$8.06M Sell
135,200
-43,600
-24% -$1.96M ﹤0.01% 2336
2019
Q3 		$6.55M Buy
178,800
+39,900
+29% +$1.58M ﹤0.01% 2396
2019
Q2 		$6.46M Buy
138,900
+104,500
+304% +$4.91M ﹤0.01% 2384
2019
Q1 		$1.38M Sell
34,400
-98,900
-74% -$4.44M ﹤0.01% 4374
2018
Q4 		$6.13M Sell
133,300
-216,600
-62% -$10.4M ﹤0.01% 2066
2018
Q3 		$15.5M Buy
349,900
+247,800
+243% +$11.4M 0.01% 1525
2018
Q2 		$4M Sell
102,100
-514,700
-83% -$26M ﹤0.01% 3009
2018
Q1 		$44.6M Buy
616,800
+455,200
+282% +$33.4M 0.02% 714
2017
Q4 		$10.6M Buy
161,600
+57,400
+55% +$3.09M ﹤0.01% 1772
2017
Q3 		$5.22M Sell
104,200
-87,900
-46% -$4.24M ﹤0.01% 2439
2017
Q2 		$8.89M Sell
192,100
-40,200
-17% -$1.48M ﹤0.01% 1804
2017
Q1 		$8.2M Buy
232,300
+175,100
+306% +$4.01M ﹤0.01% 1825
2016
Q4 		$716K Sell
57,200
-7,300
-11% -$86.9K ﹤0.01% 6232
2016
Q3 		$893K Sell
64,500
-7,000
-10% -$79.3K ﹤0.01% 5007
2016
Q2 		$706K Sell
71,500
-61,400
-46% -$1.02M ﹤0.01% 5515
2016
Q1 		$2.25M Buy
132,900
+81,000
+156% +$1.3M ﹤0.01% 3559
2015
Q4 		$1.16M Sell
51,900
-109,900
-68% -$2.77M ﹤0.01% 5126
2015
Q3 		$3.82M Sell
161,800
-130,900
-45% -$8.22M ﹤0.01% 3078
2015
Q2 		$23.9M Sell
292,700
-8,900
-3% -$871K 0.01% 1146
2015
Q1 		$27.9M Buy
+301,600
New +$19.5M 0.01% 989

Other funds holding ESPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's ESPR Position: Q1 2026 in Review

Susquehanna International Group reduced its Esperion Therapeutics (ESPR) stake by 9.1% in Q1 2026, selling an estimated $270K and leaving 850,505 shares worth $2.33M. The position accounts for ﹤0.01% of the portfolio, ranked #5814.

Susquehanna International Group first reported a position in ESPR in Q4 2014 and has held it in 38 quarters since. The position peaked at $20.9M in Q2 2015. 205 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.

  • Susquehanna International Group held 850,505 shares of Esperion Therapeutics worth $2.33M as of Q1 2026.
  • Susquehanna International Group sold 85,414 Esperion Therapeutics shares in Q1 2026, an estimated $270K.
  • Esperion Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5814 holding.
  • Susquehanna International Group first reported a position in Esperion Therapeutics in Q4 2014 and has held it in 38 quarters since.
  • Susquehanna International Group's Esperion Therapeutics position peaked at $20.9M in Q2 2015.
  • 205 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.